What is Immunocore Holdings plc's (IMCR) StockRank?

MoatMap's StockRank for Immunocore Holdings plc (IMCR) is 44/100, with a Hold signal. This is a composite score combining Quality (42), Value (47), and Momentum (46) factor ranks across MoatMap's 20,000+ stock universe.

Does Immunocore Holdings plc have an economic moat?

Immunocore Holdings plc (IMCR) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Immunocore Holdings plc a buy, hold, or sell?

MoatMap's current signal for Immunocore Holdings plc (IMCR) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Immunocore Holdings plc in?

Immunocore Holdings plc (IMCR) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IMCR

HOLDREMOVE

Immunocore Holdings plc · Healthcare · United Kingdom · $1.5B · Avg Vol: $11M/d

StockRank

P/E (TTM)

—

ROE

-7.1%

D/E

1.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

While Immunocore possesses innovative T-cell receptor technology, it is an early-commercial biotech company that does not meet our strict quality compounder criteria, lacking consistent high ROIC and predictable free cash flow.

COMPANY DESCRIPTION

Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing novel T-cell receptor (TCR) based immunotherapies for cancer and infectious diseases, with its lead product, Kimmtrak, approved for uveal melanoma. The company possesses a proprietary ImmTAX platform, which allows it to engineer high-affinity TCRs to target intracellular antigens, a significant competitive advantage over traditional antibody therapies. As a leading innovator in TCR-based immunotherapies, Immunocore is a clinical and commercial-stage biotech with a validated platform, holding significant intellectual property in a cutting-edge field.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	174M	249M	310M	400M	31.9%
EPS	-1.09	-1.13	-1.02	-0.71	—
Shares	48M	50M	50M	51M	+5.4%
Debt	81M	85M	433M	437M	75.0%
Equity	339M	369M	361M	381M	4.0%
Op CF	-49M	3M	26M	-11M	786.4%
Inv CF	-2M	-5M	-355M	-16M	—
Fin CF	145M	34M	344M	12M	—

PRICE (1M)-6.6%

SMA 50SMA 200

$28.60

RSI (14)

47.7

52W High

$40.72

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-0.8%43.4

ROE

-7.1%37.3

GP/Assets

12.5%30.8

Op. Margin

6.8%59.4

FCF/Assets

5.5%72.5

Piotroski

—28.7

Int. Cover

-0.6x38.4

D/E Ratio

1.11x13.0

Current Ratio

4.18x65.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-93.6x96.1

P/FCF

25.2x46.8

P/B

3.7x32.0

P/S

3.6x50.9

Div Yield

—N/A

Momentum

52W High %

70%56.8

RS 6M

-32%40.0

SMA 50/200

0.89x33.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-20%14.6

Q Growth

158%89.8

FUNDAMENTALS

Market Cap

$1.5B

P/E (Forward)

-43.1x

Gross Margin

32.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMCR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
IMCR	Immunocore Holdings plc(you)	$1.5B	44	HOLD
OXB.L	Oxford Biomedica plc	$1.0B	38	HOLD
ONT.L	Oxford Nanopore Technologies plc	$1.9B	30	SELL
GNS.L	Genus plc	$2.1B	58	HOLD
CNTA	Centessa Pharmaceuticals plc	$6.2B	47	HOLD
SCLP.L	Scancell Holdings plc	$333M	37	HOLD
AUTL	Autolus Therapeutics plc	$471M	22	SELL
AVCT.L	Avacta Group Plc	$472M	14	STRONG SELL
ROIV	Roivant Sciences Ltd.	$21.5B	45	HOLD
BCYC	Bicycle Therapeutics plc	$326M	11	STRONG SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Immunocore Holdings plc (IMCR) — Stock Score Summary

Immunocore Holdings plc (IMCR) has a MoatMap StockRank of 44/100 based on Quality (42/100), Value (47/100), and Momentum (46/100) factor scores. The current signal is HOLD. While Immunocore possesses innovative T-cell receptor technology, it is an early-commercial biotech company that does not meet our strict quality compounder criteria, lacking consistent high ROIC and predictable free cash flow.

Key Financial Metrics

Price	$28.60
Market Cap	$1.5B
P/E (Forward)	-43.10
Price/Book	3.74
Return on Equity	-7.1%
Return on Invested Capital	-0.8%
Debt/Equity	110.67
Gross Margin	32.3%
Operating Margin	6.8%
Revenue Growth	13.6%
Free Cash Flow	$59M

Immunocore Holdings plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Immunocore Holdings plc’s (IMCR) StockRank?: MoatMap’s StockRank for Immunocore Holdings plc (IMCR) is 44/100, with a Hold signal. It is a composite of Quality (42), Value (47), and Momentum (46) factor ranks across MoatMap’s 20,000+ stock universe.
Does Immunocore Holdings plc have an economic moat?: Immunocore Holdings plc (IMCR) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Immunocore Holdings plc a buy, hold, or sell?: MoatMap’s current signal for Immunocore Holdings plc (IMCR) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Immunocore Holdings plc in?: Immunocore Holdings plc (IMCR) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).